Effects of Continuous Infusion Therapies on Non-Motor Symptoms in Advanced Parkinson’s Disease: A Systematic Review
Brain Sciences · 30.06.2026 · 16 (7) · 698
DOI: 10.3390/brainsci16070698 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain Sciences, online erschienen am 30.06.2026. Verfasst von Domiziana Rinaldi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome, 00189 Rome, Italy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Non-motor symptoms (NMS) are highly prevalent in advanced Parkinson’s disease (PD) and substantially affect quality of life. Continuous infusion therapies are established treatment options for motor fluctuations not controlled by oral medication, but their effects on NMS remain incompletely characterized. We aimed to evaluate the effects of continuous infusion therapies on NMS in advanced PD.
Methods
A systematic review was conducted according to PRISMA guidelines. PubMed, Embase, and Cochrane were searched for English-language original studies published between January 2005 and 1 March 2026. Eligible studies included patients with PD treated with levodopa–carbidopa intestinal gel (LCIG), continuous subcutaneous apomorphine infusion (CSAI), subcutaneous levodopa formulations, or levodopa–entacapone–carbidopa intestinal gel (LECIG) and reported quantitative NMS outcomes. Due to methodological heterogeneity, results were synthesized qualitatively.
Results
Fifty-four studies were included. Most evaluated LCIG (n = 38), followed by CSAI (n = 14), subcutaneous levodopa formulations (n = 6), and LECIG (n = 2). Overall, 4157 patients were assessed at baseline and 2919 at follow-up. Global non-motor burden improved in 33/45 (73.3%) baseline-to-follow-up comparisons. NMSS total score decreased from 84.4 ± 35.2 to 54.9 ± 17.6. The most consistent benefits were observed for sleep/fatigue and gastrointestinal symptoms. Sleep/fatigue outcomes improved in 26/31 (83.9%) baseline-to-follow-up comparisons. Cognitive outcomes were mostly stable, while cardiovascular, urinary, sexual, and mood-specific outcomes showed less consistent benefit.
Conclusions
Continuous infusion therapies may be associated with reduced global non-motor burden in advanced PD, particularly sleep/fatigue and gastrointestinal symptoms. Evidence is strongest for LCIG, while data for CSAI, LECIG, and subcutaneous levodopa formulations remain limited.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome, 00189 Rome, Italy.
- Department of Neuroscience "Rita Levi Montalcini", University of Turin, 10126 Turin, Italy.
- Struttura Complessa Neurologia 2U, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, 10126 Turin, Italy.
ORCID-Profile: Domiziana Rinaldi, Lanfranco De Carolis, Claudia Ledda, Silvia Galli, Marco Salvetti, Gabriele Imbalzano
Zitieren
APA
Rinaldi, D., De Carolis, L., Ledda, C., Galli, S., Giovannelli, M., Romagnolo, A., Zibetti, M., Salvetti, M., Lopiano, L., & Imbalzano, G. (2026). Effects of Continuous Infusion Therapies on Non-Motor Symptoms in Advanced Parkinson’s Disease: A Systematic Review. Brain Sciences, 16(7), 698. https://doi.org/10.3390/brainsci16070698
Vancouver
Rinaldi D, De Carolis L, Ledda C, Galli S, Giovannelli M, Romagnolo A, et al. Effects of Continuous Infusion Therapies on Non-Motor Symptoms in Advanced Parkinson’s Disease: A Systematic Review. Brain Sciences. 2026;16(7):698. doi:10.3390/brainsci16070698
BibTeX
@article{Rinaldi2026,
author = {Rinaldi, Domiziana and De Carolis, Lanfranco and Ledda, Claudia and Galli, Silvia and Giovannelli, Morena and Romagnolo, Alberto and Zibetti, Maurizio and Salvetti, Marco and Lopiano, Leonardo and Imbalzano, Gabriele},
title = {Effects of Continuous Infusion Therapies on Non-Motor Symptoms in Advanced Parkinson’s Disease: A Systematic Review},
journal = {Brain Sciences},
year = {2026},
volume = {16},
number = {7},
pages = {698},
doi = {10.3390/brainsci16070698}
}
EUVIMED